London
· Delayed Price · Currency is GBP · Price in USD Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of GBP 400.78 million. The enterprise value is 289.05 million.
| Market Cap | 400.78M |
| Enterprise Value | 289.05M |
Important Dates
The next estimated earnings date is Friday, February 28, 2025.
| Earnings Date | Feb 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +32.62% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 70.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 4.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.74 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.87, with a Debt / Equity ratio of 0.01.
| Current Ratio | 16.87 |
| Quick Ratio | 16.52 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9,951.00 |
Financial Efficiency
Return on equity (ROE) is -72.96% and return on invested capital (ROIC) is -43.44%.
| Return on Equity (ROE) | -72.96% |
| Return on Assets (ROA) | -39.56% |
| Return on Capital (ROIC) | -43.44% |
| Revenue Per Employee | 658 |
| Profits Per Employee | -1.31M |
| Employee Count | 59 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.82% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -27.82% |
| 50-Day Moving Average | 8.03 |
| 200-Day Moving Average | 7.21 |
| Relative Strength Index (RSI) | 42.86 |
| Average Volume (20 Days) | 8,446 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.21 |
Income Statement
In the last 12 months, Altimmune had revenue of GBP 38,797 and -77.24 million in losses. Loss per share was -1.14.
| Revenue | 38,797 |
| Gross Profit | -59.17M |
| Operating Income | -74.24M |
| Pretax Income | -77.24M |
| Net Income | -77.24M |
| EBITDA | -74.01M |
| EBIT | -74.24M |
| Loss Per Share | -1.14 |
Balance Sheet
The company has 103.99 million in cash and 1.32 million in debt, giving a net cash position of 102.67 million.
| Cash & Cash Equivalents | 103.99M |
| Total Debt | 1.32M |
| Net Cash | 102.67M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 99.51M |
| Book Value Per Share | 1.40 |
| Working Capital | 102.31M |
Cash Flow
| Operating Cash Flow | -58.28M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -191,366.37% |
| Pretax Margin | -199,077.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.62% |
| Shareholder Yield | -32.62% |
| Earnings Yield | -19.27% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Altimmune has an Altman Z-Score of 12.19.
| Altman Z-Score | 12.19 |
| Piotroski F-Score | n/a |